Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma
This cohort study examines treatment with neoadjuvant-intent cemiplimab or pembrolizumab for patients with locoregionally advanced cutaneous squamous cell carcinoma in a clinical setting.
Source: JAMA Otolaryngology - Head and Neck Surgery - Category: ENT & OMF Source Type: research
More News: Cancer & Oncology | Carcinoma | ENT & OMF | Immunotherapy | Neoadjuvant Therapy | Skin Cancer | Squamous Cell Carcinoma | Study